Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Merus(MRUS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 32.7% and a total average return of -5.0%
Truist Financial Gives a Buy Rating to Merus (MRUS)
NRG Fusion Market to Grow at a CAGR of 15% Due to Expected First Launch of Merus' Zenocutuzumab and Increased Adoption of NRG1 Fusion Biomarker Testing During the Study Period (2020-2034) | DelveInsight
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA Platform